NO20044865L - Karbonmonoksid som biomarkor og terapeutisk middel - Google Patents
Karbonmonoksid som biomarkor og terapeutisk middelInfo
- Publication number
- NO20044865L NO20044865L NO20044865A NO20044865A NO20044865L NO 20044865 L NO20044865 L NO 20044865L NO 20044865 A NO20044865 A NO 20044865A NO 20044865 A NO20044865 A NO 20044865A NO 20044865 L NO20044865 L NO 20044865L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- lung
- cancer
- biomarker
- therapeutic agent
- Prior art date
Links
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title abstract 5
- 229910002091 carbon monoxide Inorganic materials 0.000 title abstract 5
- 239000000090 biomarker Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 3
- 206010040047 Sepsis Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010023841 laryngeal neoplasm Diseases 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 230000036542 oxidative stress Effects 0.000 abstract 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 206010038687 Respiratory distress Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000019229 Spleen disease Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 208000027140 splenic disease Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Foreliggende oppfinnelse angår anvendelse av karbonmonoksid (CO) som biomarkør og terapeutisk.middel for hjerte-, lunge-, lever-, milt-, hjerne-, hud- og nyresykdommer og andre tilstander og sykdomsformer inkludert, for eksempel, astma, emfysem, bronkitt, sjokklunge ("acute respiratory distress syndrome", ARDS), sepsis, cystisk fibrose, pneumoni, interstitielle lungesykdommer, idiopatiske pulmonale sykdommer, andre lungesykdommer inkludert primær pulmonal hypertensjon, sekundær pulmonal hypertensjon, kreft, inkludert lungekreft, kreft i larynx og svelg, artritt, sårheling, Parkinsons sykdom, Aizheimers sykdom, perifer vaskulær sykdom og pulmonale vaskulære trombotiske sykdommer slik som lungeemboli. CO kan anvendes for å tilveiebringe antiinflammatorisk lindring hos pasienter som lider av oksidativt stress og andre tilstander spesielt omfattende sepsis og septisk sjokk. I tillegg kan karbonmonoksid anvendes som biomarkør eller terapeutisk middel for å redusere åndedrettsbesvær hos lungetransplantasjonspasienter og for å redusere eller inhibere oksidativt stress og inflammasjon hos transplantasjonspasienter.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/014836 WO2003094932A1 (en) | 2002-05-09 | 2002-05-09 | Carbon monoxide as a biomarker and therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20044865L true NO20044865L (no) | 2004-12-07 |
Family
ID=29418043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044865A NO20044865L (no) | 2002-05-09 | 2004-11-09 | Karbonmonoksid som biomarkor og terapeutisk middel |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1501523A4 (no) |
| JP (1) | JP2005532314A (no) |
| KR (1) | KR20040106515A (no) |
| CN (1) | CN1638781A (no) |
| AU (1) | AU2002308676B2 (no) |
| BR (1) | BR0215717A (no) |
| CA (1) | CA2484770A1 (no) |
| EA (1) | EA200401478A1 (no) |
| MX (1) | MXPA04011113A (no) |
| NO (1) | NO20044865L (no) |
| RS (1) | RS96904A (no) |
| UA (1) | UA84402C2 (no) |
| WO (1) | WO2003094932A1 (no) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
| GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
| EP2319518A1 (en) | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| ES2546280T3 (es) | 2002-04-15 | 2015-09-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Monóxido de carbono para su uso en un método para tratar íleo |
| EP1499328B1 (en) | 2002-04-15 | 2015-09-16 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Methods of treating necrotizing enterocolitis |
| CA2485465A1 (en) * | 2002-05-17 | 2003-11-27 | Yale University | Methods of treating hepatitis |
| JP2005345242A (ja) * | 2004-06-02 | 2005-12-15 | Tohoku Univ | 肺癌の化学療法治療効果の評価方法 |
| JPWO2007073005A1 (ja) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | メチル基転移反応調節物質 |
| WO2008069688A2 (en) * | 2006-12-06 | 2008-06-12 | Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| JP2010094122A (ja) | 2008-06-12 | 2010-04-30 | Keio Gijuku | バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択 |
| JP2012046470A (ja) * | 2010-08-30 | 2012-03-08 | Japan Science & Technology Agency | Ｇａｐｄｈの酵素活性阻害剤 |
| EP2663193B1 (en) * | 2011-01-14 | 2019-05-08 | Children's Hospital Los Angeles | Solution of carbon monoxide for treatment of disease, including sickle cell disease |
| US8927750B2 (en) | 2011-02-04 | 2015-01-06 | Universitaet Zu Koeln | Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules |
| US9359197B2 (en) | 2011-03-24 | 2016-06-07 | Technion Research & Development Foundation Ltd. | Method of diagnosing, prognosing and monitoring parkinson's disease |
| PT2699242T (pt) | 2011-04-19 | 2018-01-22 | Alfama Inc | Moléculas de libertação de monóxido de carbono e utilizações das mesmas |
| ES2628634T3 (es) | 2011-07-21 | 2017-08-03 | Alfama, Inc. | Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas |
| WO2014165732A1 (en) | 2013-04-04 | 2014-10-09 | The Regents Of The University Of California | System and method for utilizing exhaled breath for monitoring inflammatory states |
| EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
| TW201618795A (zh) * | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | 用以改良器官功能及延長器官移植物壽命之系統及方法 |
| JP7161737B2 (ja) * | 2017-01-30 | 2022-10-27 | 哲也 石川 | 悪性腫瘍の検査方法 |
| JP7396598B2 (ja) * | 2018-06-08 | 2023-12-12 | 住友精化株式会社 | 皮膚創傷用組成物 |
| KR102968929B1 (ko) | 2018-06-08 | 2026-05-27 | 스미토모 세이카 가부시키가이샤 | 염증성 소화 기관 질환용 조성물 |
| US12370210B2 (en) * | 2019-06-06 | 2025-07-29 | The General Hospital Corporation | Carbon monoxide as a treatment for neurodegenerative disease |
| US20230346831A1 (en) * | 2020-07-16 | 2023-11-02 | Cornell University | Methods for treating metastatic cancer using low dose carbon monoxide |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5293875A (en) * | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
| DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
| WO1998008523A1 (de) * | 1996-08-27 | 1998-03-05 | Messer Griesheim Gmbh | Wasserstoffhaltiges medikament |
| CN1507348A (zh) * | 2001-03-30 | 2004-06-23 | ɣ����ҽҩ��˾ | 用于治疗血管性、炎性和免疫疾病的一氧化碳生成性组合物 |
-
2002
- 2002-05-09 AU AU2002308676A patent/AU2002308676B2/en not_active Ceased
- 2002-05-09 EA EA200401478A patent/EA200401478A1/ru unknown
- 2002-05-09 JP JP2004503016A patent/JP2005532314A/ja active Pending
- 2002-05-09 KR KR10-2004-7018082A patent/KR20040106515A/ko not_active Ceased
- 2002-05-09 RS YUP-969/04A patent/RS96904A/sr unknown
- 2002-05-09 MX MXPA04011113A patent/MXPA04011113A/es active IP Right Grant
- 2002-05-09 BR BR0215717-9A patent/BR0215717A/pt not_active Application Discontinuation
- 2002-05-09 UA UA20041210106A patent/UA84402C2/ru unknown
- 2002-05-09 WO PCT/US2002/014836 patent/WO2003094932A1/en not_active Ceased
- 2002-05-09 CA CA002484770A patent/CA2484770A1/en not_active Abandoned
- 2002-05-09 EP EP02807413A patent/EP1501523A4/en not_active Withdrawn
- 2002-05-09 CN CNA028292995A patent/CN1638781A/zh active Pending
-
2004
- 2004-11-09 NO NO20044865A patent/NO20044865L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1501523A4 (en) | 2006-12-13 |
| EP1501523A1 (en) | 2005-02-02 |
| JP2005532314A (ja) | 2005-10-27 |
| AU2002308676B2 (en) | 2009-06-11 |
| RS96904A (sr) | 2007-02-05 |
| KR20040106515A (ko) | 2004-12-17 |
| MXPA04011113A (es) | 2005-02-14 |
| AU2002308676A1 (en) | 2003-11-11 |
| BR0215717A (pt) | 2005-02-22 |
| EA200401478A1 (ru) | 2005-12-29 |
| CN1638781A (zh) | 2005-07-13 |
| CA2484770A1 (en) | 2003-11-20 |
| WO2003094932A1 (en) | 2003-11-20 |
| UA84402C2 (ru) | 2008-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0215717A (pt) | Monóxido de carbono como um biomarcador e agente terapêutico | |
| SE0200356D0 (sv) | Novel use | |
| Minematsu et al. | Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema | |
| WO2003070188A3 (en) | Method of treating trx mediated diseases | |
| WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
| HRP20050432B1 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary diseases | |
| ATE484522T1 (de) | Menschliche antikörper gegen timp-1 | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| MXPA04006206A (es) | Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico. | |
| NO20072466L (no) | Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister | |
| NO20052348L (no) | Behandling av hemoragisk sjokk | |
| DE60140871D1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| PL1951674T3 (pl) | Pochodne sulfonamidowe i ich zastosowania do modulowania metaloproteinaz | |
| Fitton et al. | Impact of secondary pulmonary hypertension on lung transplant outcome | |
| NO20054336L (no) | Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer | |
| NO20065079L (no) | Materialer og metoder for behandling av koaguleringssykdommer | |
| Talwalkar et al. | Outcome of isolated coronary artery bypass surgery in octogenarians | |
| HUP0203152A2 (hu) | Eljárás és kompozíciók pulmonalis betegségek kezelésére | |
| WO2004045530A3 (en) | Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors | |
| PT1091933E (pt) | Beta-dicetonas e sua utilizacao | |
| WO2023173036A3 (en) | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease | |
| Löfdahl | COPD and co‐morbidities, with special emphasis on cardiovascular conditions | |
| YANG et al. | The Impact of the Jagged1/Notch1 Signalling Pathway on Endothelial-mesenchymal Transition in Idiopathic Pulmonary Fibrosis | |
| SI1828160T1 (sl) | Sulfonil amino cikliäśni derivati in njihova uporaba kot mmp-inhibitorji | |
| YU78800A (sh) | Supstituisani beta-diketoni i njihova upotreba |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |